References
- Bristol-Myers Squibb Company (2002) . Sustiva product information . Princeton , NJ : Bristol-Meyers Squibb Company .
- Carr , A. 2004 . Antiretroviral therapy for previously untreated HIV-1 infected adults: 2NN, or just one? . Lancet , 363 : 1248 – 1250 .
- Harrington , R.D. 1999 . Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate . Archives of Internal Medicine , 159 : 2221 – 2224 .
- Henry , J.A. and Hill , I.R. 1998 . Fatal interaction between ritonavir and MDMA . Lancet , 352 : 1751 – 1752 .
- Hirscel , B. 2002 . Switching from protease inhibitors to efavirenz: Differences in efficacy and tolerability among risk groups. A case control study from the Swiss HIV cohort . AIDS , 16 : 381 – 385 .
- Montaner , J.S.G. , et al. (2002) . FOCUS study: Saquinavir QD regimen versus efavirenz QD regimen 48-week analysis in HIV infected patients . 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy , September , San Diego .
- Perez-Molina , J.A. 2002 . Safety and tolerance of efavirenz in different antiretroviral regimens: Results from a National Multicenter Prospective Study in 1,033 HIV-infected patients . HIV Clinical Trials , 3 : 279 – 286 .
- Staszewski , S. 1999 . Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-infection in adults . New England Journal of Medicine , 341 : 1865 – 1873 .